Goodman Advisory Group’s Gilead Sciences GILD Stock Holding History

Goodman Advisory Group’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-65	Closed	-$5.45K	–	96
2024 Q3	$5.45K	Buy	+65	New	+$4.96K	﹤0.01%	167
2024 Q2	–	Sell	-68,144	Closed	-$4.99M	–	188
2024 Q1	$4.99M	Sell	68,144 -9,771	-13%	-$751K	1.58%	23
2023 Q4	$6.31M	Sell	77,915 -17,821	-19%	-$1.39M	2.15%	13
2023 Q3	$7.17M	Sell	95,736 -9,599	-9%	-$738K	2.68%	9
2023 Q2	$8.12M	Sell	105,335 -3,496	-3%	-$279K	3.01%	7
2023 Q1	$9.03M	Buy	108,831 +46,240	+74%	+$3.83M	4.92%	6
2022 Q4	$5.37M	Buy	62,591 +5,267	+9%	+$417K	3.13%	9
2022 Q3	$3.54M	Buy	57,324 +36,382	+174%	+$2.29M	1.93%	11
2022 Q2	$1.29M	Buy	+20,942	New	+$1.3M	0.58%	23

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goodman Advisory Group's GILD Position: Q4 2024 in Review

Goodman Advisory Group sold out of Gilead Sciences (GILD) in Q4 2024, closing a stake of 65 shares — an estimated $5.45K sold.

Goodman Advisory Group first reported a position in GILD in Q2 2022 and held it in 9 quarters. The position peaked at $9.03M in Q1 2023. 1,887 funds tracked by Wall St. Rank hold GILD as of Q4 2024.

Goodman Advisory Group reported no remaining Gilead Sciences position as of Q4 2024 after selling out during the quarter.
Goodman Advisory Group sold 65 Gilead Sciences shares in Q4 2024, an estimated $5.45K.
Goodman Advisory Group first reported a position in Gilead Sciences in Q2 2022 and held it in 9 quarters.
Goodman Advisory Group's Gilead Sciences position peaked at $9.03M in Q1 2023.
1,887 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2024.

Based on Goodman Advisory Group's 13F filing for Q4 2024, filed 13 Feb 2025.